Advertisement

Glutamine Metabolism in Gliomas

Chapter
First Online:
Part of the Advances in Neurobiology book series (NEUROBIOL, volume 13)

Abstract

By histological, morphological criteria, and malignancy, brain tumors are classified by WHO into grades I (most benign) to IV (highly malignant), and gliomas are the most frequently occurring class throughout the grades. Similar to peripheral tumors, the growth of glia-derived tumor cells largely depends on glutamine (Gln), which is vividly taken up by the cells, using mostly ASCT2 and SN1 as Gln carriers. Tumor growth-promoting effects of Gln are associated with its phosphate-activated glutaminase (GA) (specifically KGA)-mediated degradation to glutamate (Glu) and/or with its entry to the energy- and intermediate metabolite-generating pathways related to the tricarboxylic acid cycle. However, a subclass of liver-type GA are absent in glioma cells, a circumstance which allows phenotype manipulations upon their transfection to the cells. Gln-derived Glu plays a major role in promoting tumor proliferation and invasion. Glu is relatively inefficiently recycled to Gln and readily leaves the cells by exchange with the extracellular pool of the glutathione (GSH) precursor Cys mediated by xc- transporter. This results in (a) cell invasion-fostering interaction of Glu with ionotropic Glu receptors in the surrounding tissue, (b) intracellular accumulation of GSH which increases tumor resistance to radio- and chemotherapy.

Keywords

Gliomas Glutamine Glutamate Glutathione Cell proliferation Tumor invasion Glutaminase 
This is a preview of subscription content, log in to check access.

References

  1. Aledo JC, Gómez-Fabre PM, Olalla L, Márquez J (2000) Identification of two human glutaminase loci and tissue-specific expression of the two related genes. Mamm Genome 11(12):1107–1110CrossRefPubMedGoogle Scholar
  2. Aoki C, Kaneko T, Starr A, Pickel VM (1991) Identification of mitochondrial and non-mitochondrial glutaminase within select neurons and glia of rat forebrain by electron microscopic immunocytochemistry. J Neurosci Res 28(4):531–548CrossRefPubMedGoogle Scholar
  3. Bouzier AK, Quesson B, Valeins H, Canioni P, Merle M (1999) [1-(13)C] glucose metabolism in the tumoral and nontumoral cerebral tissue of a glioma-bearing rat. J Neurochem 72(6):2445–2455CrossRefPubMedGoogle Scholar
  4. Buckingham SC, Campbell SL, Haas BR, Montana V, Robel S, Ogunrinu T, Sontheimer H (2011) Glutamate release by primary brain tumors induces epileptic activity. Nat Med 17(10):1269–1274. doi: 10.1038/nm.2453 CrossRefPubMedPubMedCentralGoogle Scholar
  5. Campos JA, Aledo JC, Segura JA, Alonso FJ, Gómez-Fabre PM, Núñez de Castro I, Márquez J (2003) Expression of recombinant human L-glutaminase in Escherichia coli: polyclonal antibodies production and immunological analysis of mouse tissues. Biochim Biophys Acta 1648(1–2):17–23CrossRefPubMedGoogle Scholar
  6. Campos-Sandoval JA, López de la Oliva AR, Lobo C, Segura JA, Matés JM, Alonso FJ, Márquez J (2007) Expression of functional human glutaminase in baculovirus system: affinity purification, kinetic and molecular characterization. Int J Biochem Cell Biol 39(4):765–773CrossRefPubMedGoogle Scholar
  7. Castell L, Vance C, Abbott R, Marquez J, Eggleton P (2004) Granule localization of glutaminase in human neutrophils and the consequence of glutamine utilization for neutrophil activity. J Biol Chem 279(14):13305–13310CrossRefPubMedGoogle Scholar
  8. Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, Matés JM, DeBerardinis RJ (2011) Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci U S A 108(21):8674–8679. doi: 10.1073/pnas.1016627108 CrossRefPubMedPubMedCentralGoogle Scholar
  9. Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, Sontheimer H (2005) Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci 25(31):7101–7110CrossRefPubMedPubMedCentralGoogle Scholar
  10. Cohen AL, Holmen SL, Colman H (2013) IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 13(5):345. doi: 10.1007/s11910-013-0345-4 CrossRefPubMedPubMedCentralGoogle Scholar
  11. Collins CL, Wasa M, Souba WW, Abcouwer SF (1998) Determinants of glutamine dependence and utilization by normal and tumor-derived breast cell lines. J Cell Physiol 176(1):166–178CrossRefPubMedGoogle Scholar
  12. Cuperlovic-Culf M, Ferguson D, Culf A, Morin P Jr, Touaibia M (2012) 1H NMR metabolomics analysis of glioblastoma subtypes: correlation between metabolomics and gene expression characteristics. J Biol Chem 287(24):20164–20175. doi: 10.1074/jbc.M111.337196 CrossRefPubMedPubMedCentralGoogle Scholar
  13. Curthoys NP, Watford M (1995) Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr 15:133–159CrossRefPubMedGoogle Scholar
  14. Davies DL, Vernadakis A (1986) Responses in astrocytic C6 glioma cells to ethanol and dibutyryl cyclic AMP. Brain Res 389(1–2):253–260CrossRefPubMedGoogle Scholar
  15. de Groot J, Sontheimer H (2011) Glutamate and the biology of gliomas. Glia 59(8):1181–1189. doi: 10.1002/glia.21113 CrossRefPubMedGoogle Scholar
  16. de Groot JF, Piao Y, Lu L, Fuller GN, Yung WK (2008) Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol 88(2):121–133. doi: 10.1007/s11060-008-9552-2 CrossRefPubMedGoogle Scholar
  17. de la Rosa V, Campos-Sandoval JA, Martín-Rufián M, Cardona C, Matés JM, Segura JA, Alonso FJ, Márquez J (2009) A novel glutaminase isoform in mammalian tissues. Neurochem Int 55(1–3):76–84. doi: 10.1016/j.neuint.2009.02.021 CrossRefPubMedGoogle Scholar
  18. de Robles P, Fiest KM, Frolkis AD, Pringsheim T, Atta C, St Germaine-Smith C, Day L, Lam D, Jette N (2015) The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro Oncol 17(6):776–783. doi: 10.1093/neuonc/nou283 CrossRefPubMedGoogle Scholar
  19. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 104(49):19345–19350CrossRefPubMedPubMedCentralGoogle Scholar
  20. DeLaBarre B, Gross S, Fang C, Gao Y, Jha A, Jiang F, Song JJ, Wei W, Hurov JB (2011) Full-length human glutaminase in complex with an allosteric inhibitor. Biochemistry 50(50):10764–10770. doi: 10.1021/bi201613d CrossRefPubMedGoogle Scholar
  21. Dolińska M, Dybel A, Zielińska M, Zabłocka B, Bużańska L, Albrecht J (2001) Glutamine transport in C6 glioma cells: substrate specificity and modulation in a glutamine-deprived medium. J Neurosci Res 66(5):959–966CrossRefPubMedGoogle Scholar
  22. Dolińska M, Dybel A, Zabłocka B, Albrecht J (2003) Glutamine transport in C6 glioma cells shows ASCT2 system characteristics. Neurochem Int 43(4–5):501–507CrossRefPubMedGoogle Scholar
  23. Elgadi KM, Meguid RA, Qian M, Souba WW, Abcouwer SF (1999) Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol Genomics 1(2):51–62PubMedGoogle Scholar
  24. Elhammali A, Ippolito JE, Collins L, Crowley J, Marasa J, Piwnica-Worms D (2014) A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. Cancer Discov 4(7):828–839. doi: 10.1158/2159-8290.CD-13-0572 CrossRefPubMedPubMedCentralGoogle Scholar
  25. Emadi A, Jun SA, Tsukamoto T, Fathi AT, Minden MD, Dang CV (2014) Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp Hematol 42(4):247–251. doi: 10.1016/j.exphem.2013.12.001 CrossRefPubMedGoogle Scholar
  26. Fan G, Sun B, Wu Z, Guo Q, Guo Y (2004) In vivo single-voxel proton MR spectroscopy in the differentiation of high-grade gliomas and solitary metastases. Clin Radiol 59(1):77–85CrossRefPubMedGoogle Scholar
  27. Fernandez C, Figarella-Branger D, Girard N, Bouvier-Labit C, Gouvernet J, Paz Paredes A, Lena G (2003) Pilocytic astrocytomas in children: prognostic factors—a retrospective study of 80 cases. Neurosurgery 53(3):544–553; discussion 554–555CrossRefPubMedGoogle Scholar
  28. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, Dang CV (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458(7239):762–765. doi: 10.1038/nature07823 CrossRefPubMedPubMedCentralGoogle Scholar
  29. Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J, Mackinnon AL, Parlati F, Rodriguez ML, Shwonek PJ, Sjogren EB, Stanton TF, Wang T, Yang J, Zhao F, Bennett MK (2014) Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther 13(4):890–901. doi: 10.1158/1535-7163.MCT-13-0870 CrossRefPubMedGoogle Scholar
  30. Hegi ME, Murat A, Lambiv WL, Stupp R (2006) Brain tumors: molecular biology and targeted therapies. Ann Oncol 17(Suppl 10):x191–x197CrossRefPubMedGoogle Scholar
  31. Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z (2010) Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A 107(16):7455–7460. doi: 10.1073/pnas.1001006107 CrossRefPubMedPubMedCentralGoogle Scholar
  32. Huang F, Zhang Q, Ma H, Lv Q, Zhang T (2014) Expression of glutaminase is upregulated in colorectal cancer and of clinical significance. Int J Clin Exp Pathol 7(3):1093–1100PubMedPubMedCentralGoogle Scholar
  33. Kallenberg K, Bock HC, Helms G, Jung K, Wrede A, Buhk JH, Giese A, Frahm J, Strik H, Dechent P, Knauth M (2009) Untreated glioblastoma multiforme: increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton MR spectroscopy. Radiology 253(3):805–812. doi: 10.1148/radiol.2533071654 CrossRefPubMedGoogle Scholar
  34. Katt WP, Ramachandran S, Erickson JW, Cerione RA (2012) Dibenzophenanthridines as inhibitors of glutaminase C and cancer cell proliferation. Mol Cancer Ther 11(6):1269–1278. doi: 10.1158/1535-7163.MCT-11-0942 CrossRefPubMedPubMedCentralGoogle Scholar
  35. Lee YZ, Yang CW, Chang HY, Hsu HY, Chen IS, Chang HS, Lee CH, Lee JC, Kumar CR, Qiu YQ, Chao YS, Lee SJ (2014) Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells. Oncotarget 5(15):6087–6101CrossRefPubMedPubMedCentralGoogle Scholar
  36. Lehnhardt FG, Bock C, Röhn G, Ernestus RI, Hoehn M (2005) Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed 18(6):371–382CrossRefPubMedGoogle Scholar
  37. Li Y, Larson P, Chen AP, Lupo JM, Ozhinsky E, Kelley D, Chang SM, Nelson SJ (2015) Short-echo three-dimensional H-1 MR spectroscopic imaging of patients with glioma at 7 tesla for characterization of differences in metabolite levels. J Magn Reson Imaging 41(5):1332–1341. doi: 10.1002/jmri.24672 CrossRefPubMedGoogle Scholar
  38. Lind-Landström T, Habberstad AH, Sundstrøm S, Torp SH (2012) Prognostic value of histological features in diffuse astrocytomas WHO grade II. Int J Clin Exp Pathol 5(2):152–158PubMedGoogle Scholar
  39. Liu J, Zhang C, Lin M, Zhu W, Liang Y, Hong X, Zhao Y, Young KH, Hu W, Feng Z (2014) Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma. Oncotarget 5(9):2635–2647CrossRefPubMedPubMedCentralGoogle Scholar
  40. Liubinas SV, Drummond KJ, Desmond PM, Bjorksten A, Morokoff AP, Kaye AH, O’Brien TJ, Moffat BA (2014) Glutamate quantification in patients with supratentorial gliomas using chemical shift imaging. NMR Biomed 27(5):570–577. doi: 10.1002/nbm.3095 CrossRefPubMedGoogle Scholar
  41. Lobo C, Ruiz-Bellido MA, Aledo JC, Márquez J, Núñez De Castro I, Alonso FJ (2000) Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells. Biochem J 348(Pt 2):257–261CrossRefPubMedPubMedCentralGoogle Scholar
  42. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109. Epub 2007 Jul 6. Review. Erratum in: Acta Neuropathol 114(5):547CrossRefPubMedPubMedCentralGoogle Scholar
  43. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H (2007) Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 67(19):9463–9471CrossRefPubMedPubMedCentralGoogle Scholar
  44. Maher EA, Marin-Valencia I, Bachoo RM, Mashimo T, Raisanen J, Hatanpaa KJ, Jindal A, Jeffrey FM, Choi C, Madden C, Mathews D, Pascual JM, Mickey BE, Malloy CR, DeBerardinis RJ (2012) Metabolism of [U-13 C]glucose in human brain tumors in vivo. NMR Biomed 25(11):1234–1244. doi: 10.1002/nbm.2794 CrossRefPubMedPubMedCentralGoogle Scholar
  45. Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XL, Rajagopalan KN, Maddie M, Vemireddy V, Zhao Z, Cai L, Good L, Tu BP, Hatanpaa KJ, Mickey BE, Matés JM, Pascual JM, Maher EA, Malloy CR, Deberardinis RJ, Bachoo RM (2012) Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab 15(6):827–837CrossRefPubMedPubMedCentralGoogle Scholar
  46. Márquez J, de la Oliva AR, Matés JM, Segura JA, Alonso FJ (2006) Glutaminase: a multifaceted protein not only involved in generating glutamate. Neurochem Int 48(6–7):465–471CrossRefPubMedGoogle Scholar
  47. Martin M, Beauvoit B, Voisin PJ, Canioni P, Guerin B, Rigoulet M (1998) Energetic and morphological plasticity of C6 glioma cells grown on 3-D support; effect of transient glutamine deprivation. J Bioenerg Biomembr 30(6):565–578CrossRefPubMedGoogle Scholar
  48. Martín-Rufián M, Nascimento-Gomes R, Higuero A, Crisma AR, Campos-Sandoval JA, Gómez-García MC, Cardona C, Cheng T, Lobo C, Segura JA, Alonso FJ, Szeliga M, Albrecht J, Curi R, Márquez J, Colquhoun A, Deberardinis RJ, Matés JM (2014) Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells. J Mol Med (Berl) 92(3):277–290. doi: 10.1007/s00109-013-1105-2 CrossRefGoogle Scholar
  49. Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, Nannepaga S, Piccirillo SG, Kovacs Z, Foong C, Huang Z, Barnett S, Mickey BE, DeBerardinis RJ, Tu BP, Maher EA, Bachoo RM (2014) Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 159(7):1603–1614. doi: 10.1016/j.cell.2 CrossRefPubMedPubMedCentralGoogle Scholar
  50. Meng G, Xia M, Xu C, Yuan D, Schnurr M, Wei J (2014) Multifunctional antitumor molecule 5′-triphosphate siRNA combining glutaminase silencing and RIG-I activation. Int J Cancer 134(8):1958–1971. doi: 10.1002/ijc.28416 CrossRefPubMedGoogle Scholar
  51. Münch C, Penndorf A, Schwalenstöcker B, Troost D, Ludolph AC, Ince P, Meyer T (2001) Impaired RNA splicing of 5′-regulatory sequences of the astroglial glutamate transporter EAAT2 in human astrocytoma. J Neurol Neurosurg Psychiatry 71(5):675–678CrossRefPubMedPubMedCentralGoogle Scholar
  52. Ohgaki H, Kleihues P (2009) Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100(12):2235–2241. doi: 10.1111/j.1349-7006.2009.01308.x CrossRefPubMedGoogle Scholar
  53. Olalla L, Gutierrez A, Campos JA, Khan ZU, Alonso FJ, Segura JA, Marquez J, Aledo JC (2002) Nuclear localization of L-type glutaminase in mammalian brain. J Biol Chem 277(41):38939–38944CrossRefPubMedGoogle Scholar
  54. Pan T, Gao L, Wu G, Shen G, Xie S, Wen H, Yang J, Zhou Y, Tu Z, Qian W (2015) Elevated expression of glutaminase confers glucose utilization via glutaminolysis in prostate cancer. Biochem Biophys Res Commun 456(1):452–458. doi: 10.1016/j.bbrc.2014.11.105 CrossRefPubMedGoogle Scholar
  55. Pawlik TM, Souba W, Sweeney TJ, Bode BP (2000) Amino acid uptake and regulation in multicellular hepatoma spheroids. J Surg Res 91(1):15–25CrossRefPubMedGoogle Scholar
  56. Pérez-Gómez C, Campos-Sandoval JA, Alonso FJ, Segura JA, Manzanares E, Ruiz-Sánchez P, González ME, Márquez J, Matés JM (2005) Co-expression of glutaminase K and L isoenzymes in human tumour cells. Biochem J 386(Pt 3):535–542CrossRefPubMedPubMedCentralGoogle Scholar
  57. Portais J, Martin M, Canioni P, Merle M (1993) Glutathione, but not glutamine, is detected in 13C-NMR spectra of perchloric acid extracts from C6 glioma cells. FEBS Lett 327(3):301–306CrossRefPubMedGoogle Scholar
  58. Portais JC, Voisin P, Merle M, Canioni P (1996) Glucose and glutamine metabolism in C6 glioma cells studied by carbon 13 NMR. Biochimie 78(3):155–164CrossRefPubMedGoogle Scholar
  59. Reitzer LJ, Wice BM, Kennell D (1979) Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 254(8):2669–2676PubMedGoogle Scholar
  60. Riemenschneider MJ, Reifenberger G (2009) Astrocytic tumors. Recent results. Cancer Res 171:3–24. doi: 10.1007/978-3-540-31206-2_1 Google Scholar
  61. Rocha CR, Garcia CC, Vieira DB, Quinet A, de Andrade-Lima LC, Munford V, Belizário JE, Menck CF (2015) Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. Cell Death Dis 6:e1727. doi: 10.1038/cddis.2015.101 CrossRefPubMedPubMedCentralGoogle Scholar
  62. Rosati A, Marconi S, Pollo B, Tomassini A, Lovato L, Maderna E, Maier K, Schwartz A, Rizzuto N, Padovani A, Bonetti B (2009) Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels. J Neurooncol 93(3):319–324. doi: 10.1007/s11060-008-9794-z CrossRefPubMedGoogle Scholar
  63. Rzeski W, Turski L, Ikonomidou C (2001) Glutamate antagonists limit tumor growth. Proc Natl Acad Sci U S A 98(11):6372–6377CrossRefPubMedPubMedCentralGoogle Scholar
  64. Santandreu FM, Brell M, Gene AH, Guevara R, Oliver J, Couce ME, Roca P (2008) Differences in mitochondrial function and antioxidant systems between regions of human glioma. Cell Physiol Biochem 22(5–6):757–768. doi: 10.1159/000185559 CrossRefPubMedGoogle Scholar
  65. Sattler R, Tyler B, Hoover B, Coddington LT, Recinos V, Hwang L, Brem H, Rothstein JD (2013) Increased expression of glutamate transporter GLT-1 in peritumoral tissue associated with prolonged survival and decreases in tumor growth in a rat model of experimental malignant glioma. J Neurosurg 119(4):878–886. doi: 10.3171/2013.6.JNS122319 CrossRefPubMedPubMedCentralGoogle Scholar
  66. Scheie D, Meling TR, Cvancarova M, Skullerud K, Mørk S, Lote K, Eide TJ, Helseth E, Beiske K (2011) Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases. Neuro Oncol 13(11):1225–1233. doi: 10.1093/neuonc/nor114 CrossRefPubMedPubMedCentralGoogle Scholar
  67. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, Tsukamoto T, Rojas CJ, Slusher BS, Rabinowitz JD, Dang CV, Riggins GJ (2010) Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 70(22):8981–8987. doi: 10.1158/0008-5472.CAN-10-1666 CrossRefPubMedPubMedCentralGoogle Scholar
  68. Shukla K, Ferraris DV, Thomas AG, Stathis M, Duvall B, Delahanty G, Alt J, Rais R, Rojas C, Gao P, Xiang Y, Dang CV, Slusher BS, Tsukamoto T (2012) Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem 55(23):10551–10563. doi: 10.1021/jm301191p CrossRefPubMedPubMedCentralGoogle Scholar
  69. Sidoryk M, Matyja E, Dybel A, Zielińska M, Bogucki J, Jaskólski DJ, Liberski PP, Kowalczyk P, Albrecht J (2004) Increased expression of a glutamine transporter SNAT3 is a marker of malignant gliomas. Neuroreport 15(4):575–578CrossRefPubMedGoogle Scholar
  70. Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin M, Hosokawa H, Nakayama T, Suzuki Y, Sugano S, Sato E, Nagao T, Yokote K, Tatsuno I, Prives C (2010) Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A 107(16):7461–7466. doi: 10.1073/pnas.1002459107 CrossRefPubMedPubMedCentralGoogle Scholar
  71. Szeliga M, Obara-Michlewska M (2009) Glutamine in neoplastic cells: focus on the expression and roles of glutaminases. Neurochem Int 55(1–3):71–75. doi: 10.1016/j.neuint.2009.01.008 CrossRefPubMedGoogle Scholar
  72. Szeliga M, Sidoryk M, Matyja E, Kowalczyk P, Albrecht J (2005) Lack of expression of the liver-type glutaminase (LGA) mRNA in human malignant gliomas. Neurosci Lett 374(3):171–173CrossRefPubMedGoogle Scholar
  73. Szeliga M, Obara-Michlewska M, Matyja E, Łazarczyk M, Lobo C, Hilgier W, Alonso FJ, Márquez J, Albrecht J (2009) Transfection with liver-type glutaminase cDNA alters gene expression and reduces survival, migration and proliferation of T98G glioma cells. Glia 57(9):1014–1023. doi: 10.1002/glia.20825 CrossRefPubMedGoogle Scholar
  74. Szeliga M, Zgrzywa A, Obara-Michlewska M, Albrecht J (2012) Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents. J Neurochem 123(3):428–436. doi: 10.1111/j.1471-4159.2012.07917.x CrossRefPubMedGoogle Scholar
  75. Szeliga M, Bogacińska-Karaś M, Różycka A, Hilgier W, Marquez J, Albrecht J (2014) Silencing of GLS and overexpression of GLS2 genes cooperate in decreasing the proliferation and viability of glioblastoma cells. Tumour Biol 35(3):1855–1862. doi: 10.1007/s13277-013-1247-4 CrossRefPubMedGoogle Scholar
  76. Szeliga M, Bogacińska-Karaś M, Kuźmicz K, Rola R, Albrecht J (2016) Downregulation of GLS2 in glioblastoma cells is related to DNA hypermethylation but not to the p53 status. Mol Carcinog 55(9):1309–1316. doi: 10.1002/mc.22372 CrossRefPubMedGoogle Scholar
  77. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M (2001) Glutamate release promotes growth of malignant gliomas. Nature Med 7(9):1010–1015CrossRefPubMedGoogle Scholar
  78. Thangavelu K, Pan CQ, Karlberg T, Balaji G, Uttamchandani M, Suresh V, Schüler H, Low BC, Sivaraman J (2012) Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. Proc Natl Acad Sci U S A 109(20):7705–7710. doi: 10.1073/pnas.1116573109 CrossRefPubMedPubMedCentralGoogle Scholar
  79. Tibbetts KM, Emnett RJ, Gao F, Perry A, Gutmann DH, Leonard JR (2009) Histopathologic predictors of pilocytic astrocytoma event-free survival. Acta Neuropathol 117(6):657–665. doi: 10.1007/s00401-009-0506-3 CrossRefPubMedGoogle Scholar
  80. Turner A, McGivan JD (2003) Glutaminase isoform expression in cell lines derived from human colorectal adenomas and carcinomas. Biochem J 370(Pt 2):403–408CrossRefPubMedPubMedCentralGoogle Scholar
  81. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research Network (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110. doi: 10.1016/j.ccr.2009.12.020 CrossRefPubMedPubMedCentralGoogle Scholar
  82. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, Wilson KF, Ambrosio AL, Dias SM, Dang CV, Cerione RA (2010) Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18(3):207–219. doi: 10.1016/j.ccr.2010.08.009. Erratum in: Cancer Cell. 2010 18(4):397CrossRefPubMedPubMedCentralGoogle Scholar
  83. Warburg O (1956) On the origin of cancer cells. Science 123(3191):309–314CrossRefPubMedGoogle Scholar
  84. Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8:519–530CrossRefPubMedPubMedCentralGoogle Scholar
  85. Wasa M, Bode BP, Abcouwer SF, Collins CL, Tanabe KK, Souba WW (1996) Glutamine as a regulator of DNA and protein biosynthesis in human solid tumor cell lines. Ann Surg 224(2):189–197CrossRefPubMedPubMedCentralGoogle Scholar
  86. Weller M, Cloughesy T, Perry JR, Wick W (2013a) Standards of care for treatment of recurrent glioblastoma—are we there yet? Neuro Oncol 15(1):4–27. doi: 10.1093/neuonc/nos273 CrossRefPubMedGoogle Scholar
  87. Weller M, Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R (2013b) Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 14(9):e370–e379. doi: 10.1016/S1470-2045(13)70168-2 CrossRefPubMedGoogle Scholar
  88. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, Hawkins C, Guha A (2011) Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 208(2):313–326. doi: 10.1084/jem.20101470 CrossRefPubMedPubMedCentralGoogle Scholar
  89. Xiang L, Xie G, Liu C, Zhou J, Chen J, Yu S, Li J, Pang X, Shi H, Liang H (2013) Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation. Biochim Biophys Acta 1833(12):2996–3005. doi: 10.1016/j.bbamcr.2013.08.003 CrossRefPubMedGoogle Scholar
  90. Yao PS, Kang DZ, Lin RY, Ye B, Wang W, Ye ZC (2014) Glutamate/glutamine metabolism coupling between astrocytes and glioma cells: neuroprotection and inhibition of glioma growth. Biochem Biophys Res Commun 450(1):295–299. doi: 10.1016/j.bbrc.2014.05.120 CrossRefPubMedGoogle Scholar
  91. Ye Z, Sontheimer H (1999) Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 59(17):4383–4391PubMedGoogle Scholar
  92. Ye ZC, Rothstein JD, Sontheimer H (1999) Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci 19(24):10767–10777PubMedGoogle Scholar
  93. Yin Y, Sun W, Xiang J, Deng L, Zhang B, Xie P, Qiao W, Zou J, Liu C (2013) Glutamine synthetase functions as a negative growth regulator in glioma. J Neurooncol 114(1):59–69. doi: 10.1007/s11060-013-1168-5 CrossRefPubMedGoogle Scholar
  94. Yu D, Shi X, Meng G, Chen J, Yan C, Jiang Y, Wei J, Ding Y (2015) Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma. Oncotarget 6(10):7619–7631CrossRefPubMedPubMedCentralGoogle Scholar
  95. Yuen TI, Morokoff AP, Bjorksten A, D’Abaco G, Paradiso L, Finch S, Wong D, Reid CA, Powell KL, Drummond KJ, Rosenthal MA, Kaye AH, O’Brien TJ (2012) Glutamate is associated with a higher risk of seizures in patients with gliomas. Neurology 79(9):883–889. doi: 10.1212/WNL.0b013e318266fa89 CrossRefPubMedGoogle Scholar
  96. Zhang J, Wang C, Chen M, Cao J, Zhong Y, Chen L, Shen HM, Xia D (2013) Epigenetic silencing of glutaminase 2 in human liver and colon cancers. BMC Cancer 13:601. doi: 10.1186/1471-2407-13-601 CrossRefPubMedPubMedCentralGoogle Scholar
  97. Zhuang Z, Qi M, Li J, Okamoto H, Xu DS, Iyer RR, Lu J, Yang C, Weil RJ, Vortmeyer A, Lonser RR (2011) Proteomic identification of glutamine synthetase as a differential marker for oligodendrogliomas and astrocytomas. J Neurosurg 115(4):789–795. doi: 10.3171/2011.5.JNS11451 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of NeurotoxicologyMossakowski Medical Research Centre, Polish Academy of SciencesWarsawPoland

Personalised recommendations

Cite chapter

Buy options